BR112021024325A2 - Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida - Google Patents

Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida

Info

Publication number
BR112021024325A2
BR112021024325A2 BR112021024325A BR112021024325A BR112021024325A2 BR 112021024325 A2 BR112021024325 A2 BR 112021024325A2 BR 112021024325 A BR112021024325 A BR 112021024325A BR 112021024325 A BR112021024325 A BR 112021024325A BR 112021024325 A2 BR112021024325 A2 BR 112021024325A2
Authority
BR
Brazil
Prior art keywords
methyl
compounds
thiazol
pyrimidin
ethyl
Prior art date
Application number
BR112021024325A
Other languages
English (en)
Inventor
Andrea Rotgeri
Antje Rottmann
Elisabeth Pook
Kai Thede
Martin Fischer Oliver
Anthony Herbert Simon
Ursula Ganzer
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of BR112021024325A2 publication Critical patent/BR112021024325A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2- (trifluoro-metil)pirimidin-5-il]etil}benzamida. a presente invenção refere-se a compostos inibidores de p2x3 da fórmula (i): (i), em que r1 e r2 são como definidos aqui, métodos de preparação dos ditos compostos, compostos intermediários úteis para a preparação dos ditos compostos, composições farmacêuticas e combinações que compreendem os ditos compostos e o uso dos ditos compostos para manufatura das composições farmacêuticas para o tratamento ou a profilaxia de doenças, em particular de distúrbios neurogênicos, como um agente único ou em combinação com outros ingredientes.
BR112021024325A 2019-06-27 2020-06-25 Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida BR112021024325A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19182797.1A EP3757103A1 (en) 2019-06-27 2019-06-27 Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
PCT/EP2020/067828 WO2020260463A1 (en) 2019-06-27 2020-06-25 Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide

Publications (1)

Publication Number Publication Date
BR112021024325A2 true BR112021024325A2 (pt) 2022-01-11

Family

ID=67105828

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024325A BR112021024325A2 (pt) 2019-06-27 2020-06-25 Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida

Country Status (18)

Country Link
US (1) US20230013419A1 (pt)
EP (2) EP3757103A1 (pt)
JP (1) JP2022538270A (pt)
KR (1) KR20220027860A (pt)
CN (1) CN114026086A (pt)
AU (1) AU2020303269A1 (pt)
BR (1) BR112021024325A2 (pt)
CA (1) CA3145204A1 (pt)
CL (1) CL2021003455A1 (pt)
CO (1) CO2021017435A2 (pt)
CR (1) CR20210686A (pt)
EC (1) ECSP21088111A (pt)
IL (1) IL289161A (pt)
JO (1) JOP20210338A1 (pt)
MA (1) MA56383A (pt)
MX (1) MX2021015853A (pt)
PE (1) PE20220219A1 (pt)
WO (1) WO2020260463A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36422A (es) 2014-12-09 2016-06-30 Evotec Ag Benzamidas sustituidas con 1,3-tiazol-2-ilo
CN114072399A (zh) * 2020-05-25 2022-02-18 中国医药研究开发中心有限公司 芳甲酰胺类化合物及其制备方法和医药用途
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
JP2023543066A (ja) * 2020-09-30 2023-10-12 ヒューマンウェル ヘルスケア （グループ） カンパニー リミテッド ベンザミド類化合物及びその使用
WO2023185931A1 (zh) * 2022-03-29 2023-10-05 人福医药集团股份公司 一种p2x3抑制剂化合物及其盐、多晶型和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
EP2091927B1 (en) * 2006-11-09 2011-07-20 F. Hoffmann-La Roche AG Thiazole and oxazole-substituted arylamides
CN102245586B (zh) * 2008-12-16 2014-07-09 霍夫曼-拉罗奇有限公司 噻二唑取代的芳基酰胺
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
UY36422A (es) * 2014-12-09 2016-06-30 Evotec Ag Benzamidas sustituidas con 1,3-tiazol-2-ilo
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
EA202092678A1 (ru) * 2018-05-15 2021-04-12 Байер Акциенгезельшафт 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
SG11202011018PA (en) * 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization

Also Published As

Publication number Publication date
JOP20210338A1 (ar) 2023-01-30
MA56383A (fr) 2022-05-04
JP2022538270A (ja) 2022-09-01
EP3990453A1 (en) 2022-05-04
WO2020260463A1 (en) 2020-12-30
ECSP21088111A (es) 2022-01-31
CN114026086A (zh) 2022-02-08
IL289161A (en) 2022-02-01
PE20220219A1 (es) 2022-02-02
MX2021015853A (es) 2022-02-03
CO2021017435A2 (es) 2022-01-17
AU2020303269A1 (en) 2022-02-03
CL2021003455A1 (es) 2022-08-05
KR20220027860A (ko) 2022-03-08
CA3145204A1 (en) 2020-12-30
CR20210686A (es) 2022-02-09
US20230013419A1 (en) 2023-01-19
EP3757103A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
BR112021024325A2 (pt) Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
BR112019009529A2 (pt) novos derivados de quinolina
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
BR112015024073A2 (pt) Derivados de 3-acetilamino-1-(fenil-heteroaril- aminocarbonil ou fenil-heteroarilcarbonilamino) benzeno para tratamento de doenças hiperproliferativas
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112017017009A2 (pt) usos de um sequestrante de formaldeído e de uma composição farmacêutica, métodos para impedir, adiar, retardar ou diminuir a transformação de um composto e para tratar câncer, e, composição farmacêutica.
BR112013011634A2 (pt) derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c]
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BR112022019057A2 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune
BR112018011777A2 (pt) composições de fenfluramina e métodos para o preparo das mesmas
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
EA202090448A1 (ru) Дигидрооксадиазиноны
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
BR112017022757A2 (pt) derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap)
BR112022021748A2 (pt) Compostos e composições para inibir a atividade de hif2a e seus métodos de uso
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112019023109A2 (pt) Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
BR112021026561A2 (pt) Uso de uma composição farmacêutica na fabricação de um medicamento para a prevenção ou tratamento de doença hepática